---
document_datetime: 2023-09-21 17:52:15
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_en.pdf
document_name: galafold-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7779204
conversion_datetime: 2025-12-25 09:32:23.27194
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | Invented name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging        | Pack size   |
|------------------|-----------------|------------|-----------------------|---------------------------|----------------------------|-------------|
| EU/1/15/1082/001 | Galafold        | 123 mg     | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/Al) | 14 capsules |